Lozenge for delivery of dextromethorphan

Details for Australian Patent Application No. 2005235254 (hide)

Owner Warner-Lambert Company LLC

Inventors Ramsay, Michael Paul; Chaudhari, Atmaram Shenfadu; Lee, Joseph; Wright, Arthur Paul Gerald

Agent Spruson & Ferguson

Pub. Number AU-A-2005235254

PCT Pub. Number WO2005/102288

Priority 10/833,215 27.04.04 US

Filing date 15 April 2005

Wipo publication date 3 November 2005

International Classifications

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 9/14 (2006.01) Medicinal preparations characterised by special physical form - Particulate form, e.g. powders

A61K 9/68 (2006.01) Medicinal preparations characterised by special physical form - chewing gum type

A61K 31/485 (2006.01) - Morphinan derivatives, e.g. morphine, codeine

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Event Publications

12 October 2006 PCT application entered the National Phase

  PCT publication WO2005/102288 Priority application(s): WO2005/102288

9 July 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005235265-Immunising against meningococcal serogroup Y using proteins

2005235248-Combinations comprising alpha-2-delta ligands and EP4 receptor antagonists